Some Potential Merit Within MeiraGTx Holdings (NASDAQ:MGTX)
· seekingalpha.com
MeiraGTx gene therapy upside: AAV2-hAQP1 for radiation xerostomia targets $3.7B market; Phase 2 data 2Q27. Click for more on MGTX stock.
Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a m...